Keypoints:
• INAVO120: Overall survival benefit with combination of inavolisib with palbociclib + fulvestrant in patients PIK3CA mutated disease
• SERENA-6: Early Intervention with camizestrant with ESR1 mutations using ctDNA
• VERITAC-2: New estrogen receptor degrader vepdegestrant showed better PFS when compared to fulvestrant
• DESTINY-Breast09: TDXd with pertuzumab showed improvement in PFS in HER2 positive breast cancer when compared to THP
• ASCENT-04: Sacituzumab with pembrolizumab in triple negative breast cancer showed promising results
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain were joined by Dr. Erika Hamilton from the Sarah Cannon Research Institute, to cover the latest advancements in breast cancer research presented at the ASCO 2025 annual meeting.
Discussion started with the INAVO120 study in the HR+ space, where we observed overall survival benefit with the combination of inavolisib, with palbociclib and fulvestrant for patients with PIK3CA mutated hormone receptor-positive, HER2-negative advanced breast cancer.
Following that we discussed SERENA-6: camizestrant use in patients with emerging ESR1 mutations using ctDNA, showed significant improvement in progression-free survival. Then we dived into a new class of drug with VERITAC-2, vepdegestrant, oral PROTAC protein degrader designed to target and degrade the estrogen receptor, which showed superior progression-free survival compared to fulvestrant, particularly in ESR1 mutated patients.
We then touched on another important study from HER2+ space, DESTINY-Breast09. This study showed significant improvement in progression-free survival with the combination of TDXd plus pertuzumab in frontline metastatic HER2+ breast cancer, challenging the traditional CLEOPATRA regimen THP.
Before closing, we talked about study from triple negative breast cancer, in PDL-1 positive patients, ASCENT-04 which showed promising results when sacituzumab combined with pembrolizumab.
Thank you for joining us in this insightful discussion, and we look forward to bringing you more updates on treatment algorithms, recent approvals, and conference highlights in future episodes.
Listen Podcast on Your Favourite Platform
